Walgreens Boots Alliance stock trades steady as investors weigh Q3 2024 earnings and turnaround plan

Walgreens Boots Alliance stock has been shaped in recent weeks by the latest quarterly earnings and a strategic reset at the global pharmacy and retail group Walgreens Boots Alliance Inc. (ISIN US9314271019), as investors digest lowered guidance and restructuring charges alongside a still sizeable dividend as of 27 June 2024.

Q3 2024 results show profit pressure

According to the companys own Q3 fiscal 2024 results release dated 27 June 2024, Walgreens Boots Alliance reported net sales of about $36.4 billion for the quarter, an increase of approximately 2.8% compared with the same quarter of the prior year.

In the same Q3 2024 period, adjusted earnings per share came in around $0.63, down roughly 32% from about $0.93 a year earlier, as restructuring charges and softer US retail trends weighed on profitability, according to the earnings release issued on 27 June 2024.

The company also recorded significant pre tax impairment and restructuring charges in Q3 2024 that pushed reported net earnings into a loss position for the quarter, highlighting the accounting impact of store closures and strategic portfolio changes described in the June 2024 communication.

Guidance cut and cost actions reshape expectations

Alongside the Q3 numbers, Walgreens Boots Alliance lowered its fiscal 2024 adjusted earnings per share guidance to a range of approximately $2.80 to $2.95, from a prior range that had been closer to $3.20 to $3.35, as stated in the 27 June 2024 Q3 2024 release, reflecting tougher operating conditions and the cost of transformation initiatives.

The same Q3 2024 update described ongoing cost reduction efforts, with management citing a multi year savings program targeting several billion dollars in cumulative savings, including store footprint optimization and operational efficiencies across US Healthcare and international businesses.

For investors, the revised guidance has become a key reference point, because it implies that the company expects full year earnings to be roughly 10% to 15% below the initial outlook, even as management continues to pursue longer term growth in healthcare services and prescription volumes.

Dividend remains a central consideration

Walgreens Boots Alliance highlighted in its fiscal 2023 annual materials that it paid a quarterly cash dividend of $0.25 per share in early 2024, which annualizes at about $1.00 per share, and represents a meaningful income stream relative to the companys share price as described in the investor information around February 2024.

In its investor communications for fiscal 2023, the company also noted that it has a long history of dividend payments, although future dividends remain subject to board approval and the evolving earnings and cash flow profile, particularly as restructuring and healthcare investments absorb capital.

Given the guidance reduction and the earnings pressure evident in Q3 2024, the sustainability of the current dividend level is frequently discussed among market participants, with attention on whether free cash flow in fiscal 2025 and beyond can comfortably cover both shareholder distributions and ongoing transformation costs.

Strategic focus on US Healthcare and retail pharmacy

Walgreens Boots Alliance continues to emphasize its US Healthcare strategy, including its VillageMD and other clinic oriented activities, alongside the core US retail pharmacy business and the Boots business in the United Kingdom, as outlined in the companys broader strategic updates on its investor relations site.

In fiscal 2023, Walgreens Boots Alliance reported total group sales of roughly $139 billion, up about 4% year over year, as the US Retail Pharmacy segment delivered modest growth and international operations reported improving trends, according to the companys annual figures summarized in its investor materials.

The companys US Healthcare segment, while still relatively small compared with retail pharmacy, showed strong double digit revenue growth in fiscal 2023 from a low base, reflecting the expansion of value based primary care and other services, but also continued operating losses at this stage, based on the fiscal 2023 segment disclosures.

Revenue up 4 percent in fiscal 2023

Walgreens Boots Alliance stated in its fiscal 2023 annual overview that group revenue increased by around 4% to about $139 billion compared with approximately $133.5 billion in fiscal 2022, driven in part by higher US prescription volumes and better international performance, providing a medium term context for the more recent Q3 2024 slowdown.

Within the fiscal 2023 period, adjusted earnings per share were reported at roughly $3.98, down from about $5.04 in fiscal 2022, illustrating that while top line expanded, margin compression and strategic spending have been weighing on profitability over the last two years, according to the companys annual earnings materials.

For investors looking at Walgreens Boots Alliance stock, the combination of modest revenue growth and declining adjusted earnings per share over fiscal 2022 and fiscal 2023 makes the turnaround narrative in fiscal 2024 and fiscal 2025 particularly important, as management aims to stabilize margins and improve returns on invested capital.

Balance sheet and financial flexibility

According to information available in the companys recent filings summarized on its investor relations site, Walgreens Boots Alliance entered fiscal 2024 with several billion dollars of net debt, reflecting both historical acquisitions and ongoing investment in healthcare ventures and digital capabilities.

The company has described objectives to maintain an investment grade credit profile, with a focus on managing leverage metrics such as debt to EBITDA over time, while funding its transformation program and shareholder returns from a combination of operating cash flow and portfolio optimization measures.

For equity holders, this balance sheet context underscores the trade off between near term earnings and cash use for restructuring, and longer term potential benefits from a more efficient store network and expanded healthcare services, all of which feeds into sentiment around Walgreens Boots Alliance stock.

Operational initiatives at store level

Walgreens Boots Alliance has been rolling out initiatives to optimize labor scheduling, improve pharmacy workflow, and strengthen inventory management in its US stores, as referenced in its recent strategic commentary published via investor communications.

The company has also discussed investments in omnichannel capabilities, including online prescription refills, same day delivery options, and digital health tools, aiming to retain and grow its customer base amid competition from other large retailers and online pharmacy offerings.

Operational improvements at store level are intended to support margins by reducing waste and increasing throughput, which, if successful, could gradually lift earnings per share over the coming fiscal years despite the pressure observed in Q3 2024.

International segment and the Boots brand

Walgreens Boots Alliance owns the Boots brand in the United Kingdom and certain other markets, and the international segment has shown improving performance compared with the early years of the pandemic, as noted in its recent annual and quarterly disclosures.

In fiscal 2023, international segment sales contributed several billion dollars to the group total, with Boots UK reporting improving footfall and sales in beauty and health categories, helping to offset more challenging dynamics in US retail pharmacy volumes.

The company has previously explored strategic options for the Boots business, according to past communications, though the current strategy focuses on improving operational performance and leveraging the brand in both stores and digital channels rather than pursuing immediate divestment.

Market context for Walgreens Boots Alliance stock

Walgreens Boots Alliance stock is listed on Nasdaq via its primary US listing, and forms part of major US equity indices, giving it visibility among both retail and institutional investors who track broad benchmarks.

Equity analysts covering the name have updated their models following the Q3 2024 earnings release and guidance cut, with consensus estimates for fiscal 2024 and fiscal 2025 adjusted downward to reflect lower expected earnings per share and the impact of ongoing restructuring efforts.

The valuation of Walgreens Boots Alliance stock, often gauged through price to earnings multiples and dividend yield metrics, therefore reflects the market balancing near term earnings risk against the potential for stabilization and growth once the current transformation phase is further advanced.

Product spotlight on pharmacy services

One of Walgreens Boots Alliance key offerings is its prescription pharmacy service, which remains central to the US Retail Pharmacy segment and generates a substantial portion of revenue through medication dispensing, counseling, and related healthcare services.

The company has highlighted growth opportunities in areas such as specialty pharmacy, vaccines, and chronic disease management support, aiming to deepen its role as a healthcare partner rather than solely a retail outlet.

Developments in these pharmacy and healthcare products are directly relevant for long term investors, because sustained growth in prescriptions and clinical services can support revenue stability even as front of store retail sales face competitive pressures.

Walgreens Boots Alliance stock and investor outlook

As of late June 2024, Walgreens Boots Alliance had communicated that fiscal 2024 adjusted earnings per share would likely land between about $2.80 and $2.95, down from a previously higher outlook and from the fiscal 2023 level of roughly $3.98, underscoring the extent of earnings pressure visible to investors.

At the same time, the companys annualized dividend of about $1.00 per share, based on the recent $0.25 quarterly payment described in early 2024, continues to offer income, though the coverage ratio versus adjusted earnings and free cash flow is increasingly scrutinized.

For investors evaluating Walgreens Boots Alliance stock, the critical variables over the next several quarters include the pace of cost savings, stabilization of US retail pharmacy and international margins, performance of the US Healthcare segment, and the companys ability to maintain balance sheet strength while executing its turnaround plan.